|
Gender, n (%)
| | |
0.869c
|
|
Male
|
67 (73.6 %)
|
30 (75 %)
| |
|
Female
|
24 (26.4 %)
|
10 (25 %)
| |
|
Age (years, mean ± SD) (range)
|
66.3 ± 9.4 (43–90)
|
66.9 ± 8.6 (47–84)
|
0.700d
|
|
Location of cancer, n (%)
| | |
0.195c
|
|
Proximal third
|
15 (16.5 %)
|
3 (7.5 %)
| |
|
Middle third
|
66 (72.5 %)
|
29 (72.5 %)
| |
|
Distal third
|
10 (11.0 %)
|
8 (20.0 %)
| |
|
Complications before stent placement, n (%)
| | |
0.601c
|
|
Yes
|
41 (46.1 %)
|
20 (50 %)
| |
|
No
|
50 (55.9 %)
|
20 (50 %)
| |
|
Local lymph node enlargement, n (%)a
| | |
0.686c
|
|
Yes
|
69 (75.8 %)
|
29 (72.5 %)
| |
|
No
|
22 (24.2 %)
|
11 (27.5 %)
| |
|
Tumor stage, n (%)b
| | |
0.437c
|
|
III
|
61 (67.0 %)
|
24 (60.0 %)
| |
|
IV
|
30 (33.0 %)
|
16 (40.0 %)
| |
|
Time of stent placement (min, mean ± SD) (range)
|
22.6 ± 4.9 (15–35)
|
20.2 ± 4.7 (14–32)
|
0.792d
|
|
Length of tumor (cm, mean ± SD) (range)
|
5.3 ± 1.3 (3–10)
|
5.5 ± 1.5 (2.5–8)
|
0.139d
|
|
Length of stent (cm, mean ± SD) (range)
|
9.3 ± 2.0 (6–16)
|
10.5 ± 1.6 (6–14)
|
0.274d
|
|
Esophagus dilation, n (%)
| | |
0.775c
|
|
Yes
|
57 (62.6 %)
|
24 (60 %)
| |
|
No
|
34 (37.4 %)
|
16 (40 %)
| |
